Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III

被引:47
|
作者
Iskandar, Mazen E. [1 ]
Bonomo, Giovanni [1 ]
Avadhani, Vaidehi [2 ]
Persky, Mark [3 ]
Lucido, David [4 ,5 ]
Wang, Beverly [2 ]
Marti, Jennifer L. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Div Endocrine Surg, Dept Surg, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Dept Biostat, New York, NY 10029 USA
[5] Mt Sinai Beth Israel, Mt Sinai Hlth Syst, New York, NY USA
关键词
FINE-NEEDLE-ASPIRATION; UNDETERMINED SIGNIFICANCE; FOLLICULAR LESION; PREDICTIVE-VALUE; FOLLOW-UP; SYSTEM; CYTOPATHOLOGY; MANAGEMENT; ATYPIA; IMPACT;
D O I
10.1016/j.surg.2014.10.004
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Several recent analyses of indeterminate thyroid nodules classified as Bethesda III (follicular lesion of undetermined significance) have reported considerably greater rates of malignancy than those initially reported by the Bethesda System for Reporting Cytopathology (BSRTC). These values, however, may be overestimates owing to several sources of bias, such as referral, selection, and publication biases. Our aim was to analyze the prevalence of malignancy in Bethesda III and IV thyroid nodules in a comprehensive health system less prone to institutional referral bias, excluding incidental carcinomas, and we examine the literature for publication bias. Methods. We performed a retrospective analysis with pathologic re-review of 119 patients with Bethesda III/IV cytology undergoing surgery in a comprehensive health system by examining patient and nodule characteristics. A review of the literature was performed and analyzed for publication bias. Results. The malignancy rate in resected thyroid nodules was 13% (6/48) for Bethesda III and 28% (20/71) for Bethesda IV. There were 9 of 119 patients (8%) with incidental microcarcinomas. Age <30 years was associated with an increased risk of malignancy (odds ratio, 25.8; P = .005). Sex, nodule size, and ultrasonographic features were not associated with risk of malignancy. Analysis of the literature was indicative of publication bias for Bethesda III cohorts, with reported rates positively skewed (P = .039). Conclusion. In a comprehensive health system, the rate of malignancy in Bethesda III nodules was similar to the range reported by the BSRTC. Recent reports of greater rates of malignancy may be attributable to institutional referral patterns, operative selection, inclusion of incidental microcarcinomas, and publication bias.
引用
收藏
页码:510 / 517
页数:8
相关论文
共 50 条
  • [31] Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review
    Rao, Karthik Nagaraja
    Randolph, Gregory W.
    Lopez, Fernando
    Zafereo, Mark
    Coca-Pelaz, Andres
    Piazza, Cesare
    Dange, Prajwal
    Rodrigo, Juan Pablo
    Stenman, Goeran
    de Keizer, Bart
    Nixon, Iain
    Sinha, Shriyash
    Leboulleux, Sophie
    Maekitie, Antti A.
    Agaimy, Abbas
    Thompson, Lester
    Ferlito, Alfio
    ENDOCRINE, 2024, 85 (02) : 473 - 492
  • [32] Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience
    Koseoglu, Derya
    Ozdemir Baser, Ozden
    Cetin, Zeynep
    DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (10) : 1110 - 1115
  • [33] Diagnostic value of the European Thyroid imaging reporting and data system in stratifying the malignancy risk of Bethesda category III nodules
    Dimitrova, I.
    Shinkov, A.
    Kovatcheva, R.
    Ivanova, R.
    VIRCHOWS ARCHIV, 2019, 475 : S150 - S150
  • [34] Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
    Yoo, Mi Ri
    Gweon, Hye Mi
    Park, Ah Young
    Cho, Kyung Eun
    Kim, Jeong-Ah
    Youk, Ji Hyun
    Son, Eun Ju
    PLOS ONE, 2015, 10 (06):
  • [35] An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules
    Taccogna, Silvia
    Papini, Enrico
    Novizio, Roberto
    D'Angelo, Martina
    Turrini, Luca
    Persichetti, Agnese
    Pontecorvi, Alfredo
    Guglielmi, Rinaldo
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [36] Thyroid imaging reporting and data system in assessment of cytological Bethesda Category III thyroid nodules
    Mao, Feng
    Xu, Hui-Xiong
    Zhao, Chong-Ke
    Bo, Xiao-Wan
    Li, Xiao-Long
    Li, Dan-Dan
    Liu, Bo-Ji
    Zhang, Yi-Feng
    Xu, Jun-Mei
    Qu, Shen
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2017, 65 (02) : 163 - 173
  • [37] Value of Thyroid Imaging Reporting and Data System in Initial Bethesda Category III Thyroid Nodules
    Yan, Caoxin
    Luo, Zhiyan
    Lin, Zimei
    Xu, Shouxing
    Luo, Yunkai
    Chen, Jian
    SCIENTIFIC PROGRAMMING, 2021, 2021
  • [38] WHICH FACTORS ARE ASSOCIATED WITH MALIGNANCY IN THYROID NODULES CLASSIFIED AS BETHESDA CATEGORY 3 (AUS/FLUS) AND HOW DO THEY INFLUENCE THE PATIENT'S MANAGEMENT?
    Kaya, C.
    Bozkurt, E.
    Mut, D. Turkyilmaz
    Mihmanli, M.
    Uludag, M.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2019, 15 (04) : 491 - 496
  • [39] Predictors of Malignancy in Patients With a Repeated Diagnosis of Bethesda Category in Thyroid Nodules Who Underwent Surgery
    Vural, Veli
    Calis, Hasan
    Mayir, Burhan
    Tasdoven, Ilhan
    Comcali, Bulent
    Yilmaz, Osman Cem
    Dinc, Tolga
    Dandin, Ozgur
    Cakmak, Guldeniz Karadeniz
    Emre, Ali Ugur
    Yilmaz, Nusret
    Arici, Cumhur
    DIAGNOSTIC CYTOPATHOLOGY, 2025,
  • [40] Risk Stratification of Thyroid Nodules Diagnosed as Bethesda Category III by Ultrasound, Size, and Cytology
    Ahn, Hye Shin
    Na, Dong Gyu
    Kim, Ji-Hoon
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (10) : 924 - 933